Market Overview:
The global vascular endothelial growth factor (VEGF) inhibitors market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market is segmented by type, application, and region. By type, the market is divided into VEGF-A inhibitor, VEGF-B inhibitor, VEGF-C inhibitor, and VEGF-D inhibitor. By application, the market is classified into oncology and ophthalmology. Geographically, the global vascular endothelial growth factor (VEGF) inhibitors market is segmented into North America, Latin America Europe Asia Pacific and Middle East & Africa. The increasing prevalence of cancer across the globe drives the demand for vascular endothelial growth factor (VEGF) inhibitors in oncology applications. The growing geriatric population leads to an increase in age-related macular degeneration cases which in turn boosts demand for these drugs in ophthalmology applications . Some of the key players operating in this market are Roche Holdings AG., Novartis AG., Regeneron Pharmaceuticals Inc., Bayer AG., Pfizer Inc.
 Inhibitors Industry Outlook.svg)
Product Definition:
Vascular endothelial growth factor (VEGF) inhibitors are a type of drug that blocks the effects of VEGF. They are used to treat conditions such as cancer, macular degeneration, and diabetic retinopathy.
VEGF-A Inhibitor:
The vascular endothelial growth factor (VEGF) inhibitors market is expected to grow at a significant rate during the forecast period. The factors that propel the growth of this market are increasing prevalence of chronic diseases such as diabetic retinopathy, macular degeneration, and others. According to National Eye Institute estimates in 2016 around 2.0 million people in U.
VEGF-B Inhibitor:
VEGF-B inhibitor is a type of medication that decreases the growth of blood vessels. The main goal of VEGF inhibitors is to decrease the amount of blood vessel damage or disease progression. Some people with diabetes have a higher risk for developing diabetic eye disease, which may be vision loss due to bleeding inside the eye (ophthalmic artery) or in the retina (cataract).
The FDA has approved two drugs so far, Lucentis.
Application Insights:
On the basis of application, the global vascular endothelial growth factor (VEGF) inhibitors market is segmented into oncology and ophthalmology. In 2017, the oncology segment dominated with a revenue share of over 60% in terms of revenue as well as volume. Increasing cancer prevalence is one of the major drivers for this growth. According to WHO, it has been estimated that 1 in 6 women and 1 in 5 men are estimated to develop cancer during their life span. Rising geriatric population along with increasing cases associated with genetic disorders are some other factors driving this market towards oncology applications.
The ophthalmology application segment is expected to witness significant growth during forecast years due to rising number of patients suffering from eye diseases such as diabetic retinopathy or macular degeneration which requires regular checkups.
Regional Analysis:
North America dominated the global market in 2017. The growth of this region can be attributed to the presence of major players, such as Pfizer Inc.; Genentech; and Novartis AG. These companies are engaged in extensive R&D activities for the development of novel drugs targeting VEGF molecules. Moreover, these entities hold a strong distribution network that enables easy access to these inhibitors for patients across North America.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising incidences of various oncological diseases coupled with growing target population base in this region (i.e., geriatric population). Furthermore, increasing healthcare expenditure levels by governments and rising awareness about early diagnosis are some other factors driving regional market growth during the forecast period from 2018 to 2030 (i).e.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the VEGF inhibitors market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for VEGF inhibitors in the coming years.
- Rising awareness about targeted therapies: There has been a rising awareness among physicians and patients about targeted therapies such as VEGF inhibitors over traditional chemotherapy regimens due to their better efficacy and fewer side effects profiles These factors are likely to propel demand for these drugs in the coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Research Report
By Type
VEGF-A Inhibitor, VEGF-B Inhibitor, VEGF-C Inhibitor, VEGF-D Inhibitor
By Application
Oncology, Ophthalmology
By Companies
Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Report Segments:
The global Vascular Endothelial Growth Factor (VEGF) Inhibitors market is segmented on the basis of:
Types
VEGF-A Inhibitor, VEGF-B Inhibitor, VEGF-C Inhibitor, VEGF-D Inhibitor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Ophthalmology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Sanofi.
 Inhibitors Market Overview.svg)
Highlights of The Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- VEGF-A Inhibitor
- VEGF-B Inhibitor
- VEGF-C Inhibitor
- VEGF-D Inhibitor
- By Application:
- Oncology
- Ophthalmology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vascular Endothelial Growth Factor (VEGF) Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
VEGF inhibitors are medications that block the action of VEGF. This can help to reduce the growth of blood vessels in the body.
Some of the major players in the vascular endothelial growth factor (vegf) inhibitors market are Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi..
The vascular endothelial growth factor (vegf) inhibitors market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Vascular Endothelial Growth Factor (VEGF) Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size & Forecast, 2018-2028
4.5.1 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size and Y-o-Y Growth
4.5.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Type
5.2.1 VEGF-A Inhibitor
5.2.2 VEGF-B Inhibitor
5.2.3 VEGF-C Inhibitor
5.2.4 VEGF-D Inhibitor
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Ophthalmology
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Analysis and Forecast
9.1 Introduction
9.2 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Type
9.6.1 VEGF-A Inhibitor
9.6.2 VEGF-B Inhibitor
9.6.3 VEGF-C Inhibitor
9.6.4 VEGF-D Inhibitor
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Ophthalmology
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Analysis and Forecast
10.1 Introduction
10.2 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Type
10.6.1 VEGF-A Inhibitor
10.6.2 VEGF-B Inhibitor
10.6.3 VEGF-C Inhibitor
10.6.4 VEGF-D Inhibitor
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Ophthalmology
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Type
11.6.1 VEGF-A Inhibitor
11.6.2 VEGF-B Inhibitor
11.6.3 VEGF-C Inhibitor
11.6.4 VEGF-D Inhibitor
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Ophthalmology
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Analysis and Forecast
12.1 Introduction
12.2 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Type
12.6.1 VEGF-A Inhibitor
12.6.2 VEGF-B Inhibitor
12.6.3 VEGF-C Inhibitor
12.6.4 VEGF-D Inhibitor
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Ophthalmology
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Inhibitors Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Type
13.6.1 VEGF-A Inhibitor
13.6.2 VEGF-B Inhibitor
13.6.3 VEGF-C Inhibitor
13.6.4 VEGF-D Inhibitor
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Ophthalmology
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: Competitive Dashboard
14.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer AG
14.3.2 F. Hoffmann-La Roche Ltd.
14.3.3 Novartis AG
14.3.4 Regeneron Pharmaceuticals Inc.
14.3.5 Sanofi.
